Blepharoplasty Global Market Report 2024

The blepharoplasty market size has grown strongly in recent years. It will grow from $3.83 billion in 2023 to $4.2 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historical period can be attributed to various factors, including evolving aesthetic preferences and beauty standards, demographic shifts with an aging population, heightened awareness and acceptance of cosmetic procedures, and the influential role of media and celebrities in shaping beauty ideals. These dynamics collectively contributed to the increased adoption of blepharoplasty, aligning with societal trends and individual preferences during the historic period.

The blepharoplasty market size is expected to see strong growth in the next few years. It will grow to $5.76 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period can be attributed to several factors, including the rise in disposable income, cultural and social influences, the trend towards customization of procedures, the increasing popularity of medical tourism, and improved accessibility to cosmetic interventions. Major trends expected in the forecast period encompass a heightened focus on achieving natural and youthful results, the integration of advanced technology for precision and safety, the emergence of combination procedures, a growing demand for ethnic-specific blepharoplasty, and an increasing role for non-surgical alternatives in addressing aesthetic concerns. These trends collectively contribute to the projected growth and evolution of blepharoplasty in the forecasted period.

The rising demand for cosmetic surgeries is anticipated to be a significant driver propelling the growth of the blepharoplasty market in the future. Cosmetic surgeries, including procedures such as blepharoplasty, are aimed at enhancing or altering an individual's physical appearance for aesthetic purposes. Blepharoplasty specifically focuses on improving eyelid appearance by addressing issues such as excess or drooping skin, as well as fat deposits, providing individuals with the desired aesthetic enhancement. As reported by the American Academy of Facial Plastic and Reconstructive Surgery Inc. (AAFPRS) in February 2022, the number of surgical and nonsurgical facial procedures in 2021 witnessed a remarkable 40% surge compared to 2020, totaling approximately 1.4 million procedures performed. This escalating demand for cosmetic surgeries signals the potential growth of the home blepharoplasty market.

The increasing prevalence of renal disease is forecasted to drive growth within the blepharoplasty market moving forward. Renal disease, also known as chronic kidney disease (CKD), involves the gradual loss of kidney function. This medical condition can manifest in symptoms such as eye puffiness and altered eyelid positions, potentially affecting individuals considering blepharoplasty surgery. Notably, patients with renal disease should undergo renal function assessments before opting for blepharoplasty procedures. As highlighted by the National Institutes of Health in May 2023, approximately 808,000 individuals in the United States are currently managing end-stage renal disease (ESRD), with 69% undergoing dialysis and 31% having received a kidney transplant. This prevalence of renal disease contributes to the increased demand for blepharoplasty, driving growth within the market catering to such medical needs.

The projected constraint in the growth of the blepharoplasty market is primarily linked to the high cost associated with performing the procedure, limiting accessibility for some patients. Factors contributing to this elevated expense include the intricacy of the surgery, utilization of specialized equipment, and the requisite expertise of medical professionals performing the procedure. This cost barrier may hinder broader market expansion as it could render the procedure less accessible to certain patient demographics. For instance, as indicated by the National Health Service in September 2023, the cost of blepharoplasty in the UK may range between $2443.93 (£2,000) and $7330.179 (£6,000). Therefore, the significant cost involved in performing the procedure acts as a limiting factor impeding the growth potential of the blepharoplasty market.

Leading companies operating within the blepharoplasty market are strategically prioritizing the development of cutting-edge technologies, such as plasma technology, to strengthen their market position. Plasma technology involves utilizing ionized gases (plasmas) through specialized medical devices for non-surgical skin tightening and rejuvenation, particularly in areas such as the eyelids and facial regions. For example, in January 2023, Apyx Medical Corporation, a renowned US-based advanced energy technology company, introduced the latest-generation Renuvion generator, named the Apyx One Console. This multifunctional energy system is tailored for plastic and cosmetic surgeries, integrating Renuvion technology comprising helium plasma and radiofrequency technology, alongside monopolar and bipolar energy options. The console incorporates adaptive touchscreens, procedural presets, cloud connectivity, remote upgrade capabilities, gas volume monitoring, and other advanced features aimed at enhancing cosmetic surgical procedures, including eyelid surgery, thereby paving the way for more effective and advanced treatment options in the market.

In February 2023, Athenix, a prominent US-based medical practice company specializing in plastic surgery procedures, completed the acquisition of Marina Plastic Surgery and MedSpa for an undisclosed sum. This strategic move by Athenix is geared towards broadening its footprint within the plastic surgery sector while enhancing its range of services. The acquisition aligns with Athenix's strategic goals of expanding its offerings and strengthening its position in the plastic surgery industry. By integrating Marina Plastic Surgery and MedSpa into its portfolio, Athenix aims to reinforce its commitment to delivering comprehensive and innovative plastic surgery solutions. This strategic acquisition further solidifies Athenix's reputation as a trusted and reputable provider in the industry. Marina Plastic Surgery and MedSpa, the acquired entity, specializes in providing plastic surgery services, with a particular focus on offering blepharoplasty procedures.

Major companies operating in the blepharoplasty market report are Zimmer Biomet Holdings Inc., Cynosure Technologies Pvt Ltd., Galderma SA, Bausch & Lomb Incorporated., Allergan Inc, Integra LifeSciences Inc., Merz Pharma GmbH & Co. KGaA, Corza Ophthalmology, Lumenis Ltd., Cutera Inc., Stille AB, Alma Lasers Ltd, Sciton Inc, Beaver-Visitec International Holdings Inc., Sklar Surgical Instruments, Hayden Medical Inc, Gulmaher Surgico, Titan Medical Inc., Luminera Derm Ltd, Jedmed Instrument Company., Xelpov Surgical, Surgitrac Instruments UK Limited, Grand Aespio Inc., Surgical Holdings, Surgipro Inc., LightScalpel Inc., SPIRAL Surgical Co., Carnegie Surgical LLC., Ambler Surgical LLC.

North America was the largest region in the blepharoplasty market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blepharoplasty market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the blepharoplasty market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The blepharoplasty market consists of revenues earned by entities by providing transconjunctival blepharoplasty, canthoplasty, and revision blepharoplasty. The market value includes the value of related goods sold by the service provider or included within the service offering. The blepharoplasty market also includes sales of implants, eyelid cleansers and solutions, eyelid tape, and strips. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary types of blepharoplasty include upper eyelid blepharoplasty, lower eyelid blepharoplasty, and combination eyelid surgery. Upper eyelid blepharoplasty involves the surgical removal of excess skin, muscle, and fat from the upper eyelids, resulting in a rejuvenated appearance by eliminating redundant tissue and creating a more refreshed look. Blepharoplasty procedures are conducted on individuals of both genders, with end-users comprising hospitals, clinics, ambulatory surgical centers, and other medical facilities.

The blepharoplasty market research report is one of a series of new reports that provides blepharoplasty market statistics, including blepharoplasty industry global market size, regional shares, competitors with a blepharoplasty market share, detailed blepharoplasty market segments, market trends and opportunities, and any further data you may need to thrive in the blepharoplasty industry. This blepharoplasty market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.